Related Experiment Video
Updated: Jan 21, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Preventing metabolic syndrome in morbid obesity with resistance training: Reporting interindividual variability
Pedro Delgado-Floody1, Cristian Álvarez2, Eduardo Lusa Cadore3
1Department of Physical Education, Sport and Recreation, Universidad de La Frontera, Chile.
Background And Aims:
Resistant training (RT) improves health markers in obesity, but its effects in morbid obesity are unknown. We aimed to determine the effects of a RT-program in preventing/attenuating the metabolic syndrome (MetS) in patients with morbid obesity. A second aim was to report the interindividual variability in terms of improvements in MetS markers and other related co-variables.
Methods And Results:
Twenty-one adults with obesity or morbid obesity were divided into two groups based on body mass index (BMI): a control obesity (CO, n = 7, BMI ≥35 < 40.0 kg/m2) and a morbid obese group (MO, n = 14, BMI ≥40 kg/m2). Participants completed a 20-week RT-program (3 sessions/week, 4-8 exercise) using free weights. Participants were assessed for MetS markers (waist circumference, systolic and diastolic blood pressure [BP], fasting glucose, high-density lipoproteins, and triglycerides) and other co-variables (total cholesterol, low-density lipoprotein, one-maximum repetition of biceps curl, and handgrip strength, 6 min walking test). Significant reductions in MetS markers were observed in both CO and MO groups (P < 0.05 to P < 0.0001), but significant reductions in diastolic BP and increases in HDL-C were noted only in the MO group (P < 0.0001). Changes in waist circumference, and systolic and diastolic BP were significantly greater only in the MO group (P < 0.001), but the CO group presented a greater fasting glucose decreases (P < 0.0001). The prevalence of non-responders between CO and MO groups was similar in the MetS outcomes.
Conclusions:
RT promotes greater improvements in overall MetS outcomes waist circumference, BP, and plasma triglycerides in patients with morbid obesity than in obese peers, with no overall differences in the prevalence of non-responders.
Clinical Trial Number:
NCT03921853 at www.clinicaltrials.gov.
More Related Videos
08:30Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
Published on: March 15, 2018
06:04Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Obesity
What is Metabolism?
Cancer Prevention
Some...
Variables Affecting Phosphorescence and Fluorescence
Variability: Analysis
The range is a simple measure of variability, indicating the difference between the highest and...